BiomX Inc. has fundamentally reshaped its business, exiting phage therapy and pivoting into defense, security, and critical infrastructure technologies. Its former Israeli biotech subsidiary entered insolvency, all clinical programs have stopped, and Adaptive Phage Therapeutics is being wound down after a one-time $800,000 lease settlement.

The company now operates as a holding company over three Israeli-focused defense tech units: 60%-owned LADAR detection specialist DFSL, wholly owned AI security platform Zorronet, and X Security & Defense, which will receive over $3 million of 2026 internal funding. Management and the board were fully replaced and an advisory board was formed, including a former Deputy Head of the Mossad.

The filing highlights heavy dependence on government and prime defense contractors, exposure to Israeli conflict risks, NYSE American non-compliance with a deadline of September 25, 2027, extensive export-control and IIA restrictions, potential dilution from warrants and a $3,000,000 convertible note, and a sizable Zorronet earnout tied to 2026 performance.